Oncology
Cancer clinical trials
Studies of cancers and tumors of every type and site, from prevention to treatment. We’re tracking 20,602 recruiting studies in this area right now.
By phase
- Not applicable9,790
- Phase 24,449
- Phase 12,736
- Phase 1/Phase 21,687
- Phase 31,397
- Phase 2/Phase 3280
- Phase 4263
Top conditions
- Breast Cancer1,227
- Cancer661
- Prostate Cancer654
- Colorectal Cancer491
- Lung Cancer424
- Ovarian Cancer338
- Multiple Myeloma332
- Gastric Cancer296
- Acute Myeloid Leukemia292
- Pancreatic Cancer290
- Hepatocellular Carcinoma283
- Solid Tumor257
- Advanced Solid Tumor255
- Cervical Cancer232
- Head and Neck Cancer227
- Endometrial Cancer206
- Advanced Solid Tumors193
- Esophageal Cancer191
Leading sponsors
- M.D. Anderson Cancer Center450
- Fudan University313
- Sun Yat-sen University290
- Memorial Sloan Kettering Cancer Center288
- National Cancer Institute (NCI)285
- Mayo Clinic240
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences151
- City of Hope Medical Center147
- AstraZeneca134
- University Health Network, Toronto125
Where studies are running
- California1,424
- Texas638
- Arizona513
- Florida448
- Alabama420
- New York409
- Massachusetts343
- Maryland329
- New Jersey269
- Pennsylvania241
Recruiting studies20,602 total
- NCT06610682RecruitingEarly Phase 1
Plixorafenib for BRAF-mutated glioma
This study tests a new targeted drug called plixorafenib, either alone or combined with another drug (retifanlimab), for people with a BRAF-mutated brain tumor. The goal is to see if the drug can reach the brain and control the tumor, while checking for side effects.
Baltimore, MarylandAges 18 years+ - NCT03125980RecruitingPhase 3
Chemo timing before vs after colon cancer surgery
This Phase 3 study compares two schedules of a colon cancer chemo combination: starting before surgery or starting after surgery. It aims to see which timing helps people live longer and lowers cancer coming back.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06963814RecruitingPhase 1
HC006 with a PD-1 inhibitor for advanced solid tumors
This trial tests a new drug called HC006 combined with a standard immunotherapy (PD-1 inhibitor) for people with advanced solid tumors. It aims to see if the combination is safe and effective.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07293754RecruitingPhase 1/Phase 2
Study of RPTR-1-201 for advanced solid tumors
This trial tests a new drug called RPTR-1-201 for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and effective.
Grand Rapids, MichiganAges 18 years+ - NCT05837052RecruitingPhase 2
Serplulimab plus chemo after initial treatment for lung cancer
This Phase 2 study looks at how safe and effective serplulimab (an immune medicine) combined with chemotherapy is when used as a “conversion” plan—first shrinking lung cancer, then trying to remove the main tumor with surgery. It may help some people who are not initially good candidates for surgery or focused radiation to become eligible after treatment.
Hangzhou, ZhejiangAges 18–75 - NCT05837039Recruiting
Comparing caregiver and nurse views of discomfort in advanced cancer
This study compares how healthcare providers and family caregivers judge discomfort in people with advanced cancer who are very hard to rouse and may be actively dying. It aims to understand whether caregiver and staff perceptions match, which could improve comfort care for patients near the end of life.
Houston, TexasAges 18 years+ - NCT06876532Recruiting
Inflammation score and Lu-177 treatment for midgut NET
This study looks at whether a simple blood test (inflammation score) can predict how well the drug Lu-177 oxodotreotide (Lutathera) will work for people with midgut neuroendocrine tumors that have grown or spread. It may help doctors understand who benefits most from this treatment.
AngersAges 18 years+ - NCT05788744Recruiting
Testing DNA-based blood tests in early pancreatic cancer
This study looks at DNA signals from blood tests (so-called “ctDNA” and another type of DNA test) in people with early-stage pancreatic cancer. It aims to see whether these tests can help track cancer after surgery and check for signs of return.
AalborgAges Any age - NCT05812807RecruitingPhase 3
Pembrolizumab versus monitoring after triple-negative breast cancer response
This trial checks whether giving pembrolizumab (an immunotherapy) after surgery helps people with triple-negative breast cancer reduce the chance of the cancer coming back, compared with close monitoring only. It’s for patients who had no remaining invasive cancer after neoadjuvant chemotherapy plus pembrolizumab.
Birmingham, AlabamaAges 18 years+ - NCT05840562RecruitingPhase 3
Capsaicin skin patch vs duloxetine for nerve pain after chemo
This Phase 3 trial tests whether a capsaicin patch works better than duloxetine tablets to reduce painful nerve pain after chemotherapy. It aims to help people whose “gloves and socks” nerve pain has lasted after chemo.
AngersAges 18 years+ - NCT07243379RecruitingPhase 4
Studying nanocrystalline megestrol acetate for weight loss in cancer
This study tests a special form of the drug megestrol acetate (Megace) in cancer patients who have lost weight and appetite (cachexia). It aims to see if this medication can help improve weight gain and quality of life.
Zhengzhou, HenanAges 18–85 - NCT06705127RecruitingPhase 2
Radiation, chemo, and immunotherapy for HR+ breast cancer
This trial tests if giving radiation first, then chemo with an immunotherapy drug called Toripalimab, can help treat a certain type of breast cancer that has not spread to other organs. It is for people with hormone receptor positive, HER2 negative breast cancer that is growing fast.
Hangzhou, ZhejiangAges 18–75 - NCT06955767Recruiting
Looking for a new blood test to find colorectal cancer early
This trial is testing if a protein called MMP-14 in small blood particles (exosomes) can help detect colorectal cancer. If you are having a colonoscopy because of a positive stool test, you may be able to join and help researchers learn more about this possible new marker.
ReimsAges 18 years+ - NCT06433869RecruitingPhase 2
Three-drug combination for malignant ascites from digestive cancers
This trial tests three drugs (bevacizumab, serplulimab, and rmhTNF-NC) given together to treat fluid buildup in the belly caused by digestive system cancers. It’s for people whose ascites has not improved after standard treatments.
Guangzhou, GuangdongAges 18 years+ - NCT06876610Recruiting
Blood test for early breast cancer detection
This trial tests a blood test that looks for chemical changes in DNA to help diagnose breast cancer. It may offer a simpler way to detect cancer without needing a tissue sample.
Beijing, Beijing MunicipalityAges 30–75 - NCT06703177RecruitingPhase 1/Phase 2
Study of SHR-1826 combo for advanced solid tumors
This trial tests a new drug, SHR-1826, combined with other cancer treatments for people with advanced solid tumors that have not responded to prior therapy. The goal is to see if the combination is safe and effective.
Guangzhou, GuangdongAges 18–75 - NCT06956248Recruiting
Access to new treatments for advanced solid tumors
This trial offers access to experimental or non-standard cancer treatments for people with advanced solid tumors who have run out of standard options. The goal is to find new ways to treat cancers that are hard to manage.
SingaporeAges 21–99 - NCT06745687Recruiting
BCMA/CD3 antibody for high-risk smoldering myeloma
This trial tests a new medicine called a BCMA/CD3 bispecific antibody for people with a very early form of multiple myeloma called high-risk smoldering myeloma. The goal is to see if this treatment can stop the disease from getting worse.
TianjinAges 18–78 - NCT06433791Enrolling by invitationPhase 1
Testing a new drug plus radiation for brain metastases
This trial tests a new drug (ascorbate-meglumine) given before a single session of high-precision radiation (SRS) for people with newly diagnosed brain metastases. The goal is to see if the drug can make the radiation more effective.
Durham, North CarolinaAges 18 years+ - NCT06956716RecruitingPhase 1/Phase 2
Personalized mRNA vaccine for advanced bile duct cancer
This trial tests a personalized mRNA vaccine made from your tumor's genetic information. It's for people with advanced bile duct cancer that hasn't been treated yet, to see if it can help their immune system fight the cancer.
Hangzhou, ZhejiangAges 18–75 - NCT06953843RecruitingPhase 2
Radiation and Immunotherapy for Advanced Lung Cancer
This trial tests a combination of radiation and immunotherapy to see if it can make the immune system attack cancer throughout the body in people with advanced lung cancer that has spread to many places. It's for those whose cancer does not have certain genetic changes and who have not had uncontrolled brain metastases.
Chongqing, Chongqing MunicipalityAges 18–75 - NCT05087745RecruitingEarly Phase 1
TIL therapy for advanced solid tumors
This trial tests a treatment that uses your own immune cells, called TILs, to fight advanced solid tumors. The cells are taken from a biopsy of your tumor, multiplied in a lab, and then given back to you. It might help if you have tried other treatments without success, or if no standard treatment is available.
Hangzhou, ZhejiangAges 18–75 - NCT05841472RecruitingPhase 2
Camrelizumab plus chemo for advanced lung cancer without EGFR or ALK
This Phase 2 trial tests whether the immunotherapy drug camrelizumab, combined with pemetrexed and carboplatin, can work better as first treatment for advanced lung cancer that has no EGFR or ALK gene changes. You may be able to join if you have measurable disease, good enough organ function, and meet other safety rules for immune treatment.
AnamAges 19–80 - NCT05930483Recruiting
Remote weight loss program for Hispanic/Latina breast cancer survivors
This trial tests a community-style, online (remote) weight loss program for people who finished breast cancer treatment and are now trying to improve health and weight. It may help by supporting safer weight loss through diet/energy reduction and physical activity.
Seattle, WashingtonAges 18 years+
Common questions
- How many cancer clinical trials are recruiting?
- Clin2 is tracking 20,602 recruiting oncology studies from the U.S. registry right now, out of 31,289 we cover in this area in total.
- What does “Cancer” cover here?
- Studies of cancers and tumors of every type and site, from prevention to treatment. We group each study into cancer based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a cancer trial near me?
- Use the search to filter cancer studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Blood & lymphatic
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.